One of the major advantages of Bretschneider’s cardioplegia (histidine-tryptophan-ketoglutarate, HTK) is that it can provide a long period of myocardial protection with one single dose. The other cardioplegic solutions protect for only 20 to 60 minutes. A single dose of HTK provides over two hours of myocardial protection, with a maximum of 3 hours. This feature allows time-saving and avoidance of surgical interruption for re-administration of the solution. This is especially beneficial for MICS (Minimally invasive cardiac surgery). This webinar aims to provide updated evidence of the efficacy and safety of HTK solution in comparison with other alternative solutions in cardiac surgeries by summarizing the findings of 12 randomized controlled trials (RCTs) that compared HTK to other cardioplegic solutions in various cardiac surgeries. 1,327 cardiac patients were summarized, with 666 patients that had received the HTK solution. HTK has resulted significantly in shorter hospital and ICU stay. Moreover, in comparison with other cardioplegic solutions, HTK has significantly decreased the release of both CK and CK-MB. 

We look forward to your participation!

Your Köhler Campus team

About the Event

The Speaker

Registration

This event is targeted at physicians, pharmacists and healthcare professionals and is free of charge. Register to receive the link to the live webinar using the form below.